Advertisement
Canada markets closed
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7323
    +0.0025 (+0.34%)
     
  • CRUDE OIL

    83.76
    +0.95 (+1.15%)
     
  • Bitcoin CAD

    88,579.56
    +1,103.08 (+1.26%)
     
  • CMC Crypto 200

    1,398.82
    +16.25 (+1.18%)
     
  • GOLD FUTURES

    2,344.20
    +5.80 (+0.25%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ

    15,611.76
    -100.99 (-0.64%)
     
  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6821
    +0.0002 (+0.03%)
     

Why Has Valeant Stock Fallen in June?

Why Has Valeant Stock Fallen in June?

Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.